National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Atezolizumab

Synonyms

Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer

Atezolizumab

ATEZOLIZUMAB

MPDL 3280A

MPDL 328OA

MPDL-3280A

MPDL3280A

MPDL328OA

RG7446

RO5541267

Tecentriq

Definitions

A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106250

Accepted_Therapeutic_Use_For

the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%]), with no EGFR or ALK genomic tumor aberrations.

metastatic non-small cell lung cancer (NSCLC); locally advanced or metastatic urothelial carcinoma; extensive-stage small cell lung cancer (ES-SCLC)

CAS_Registry

1380723-44-3

code

C106250

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

Contributing_Source

CTRP

FDA

GDC

HemOnc

DEFINITION

A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

Display_Name

Atezolizumab

FDA_UNII_Code

52CMI0WC3Y

FULL_SYN

Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer

Atezolizumab

ATEZOLIZUMAB

MPDL 3280A

MPDL 328OA

MPDL-3280A

MPDL3280A

MPDL328OA

RG7446

RO5541267

Tecentriq

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C96024

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Atezolizumab

Maps_To

Atezolizumab

NCI_Drug_Dictionary_ID

702758

PDQ_Closed_Trial_Search_ID

702758

PDQ_Open_Trial_Search_ID

702758

Preferred_Name

Atezolizumab

prefixIRI

Thesaurus:C106250

Semantic_Type

Amino Acid, Peptide, or Protein

Pharmacologic Substance

UMLS_CUI

C3827082

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128057

Delete Subject Author Type Created
No notes to display